Key result
This editorial reviews novel evidence on cardiovascular risk factors, including haptoglobin polymorphism, adipokine profiles, polypill use, and resting heart rate in patients with diabetes and CVD.
Answers are grounded in this paper and cite their sources.
This editorial summarizes novel evidence on cardiovascular risk stratification and prevention in patients with diabetes and metabolic syndrome, highlighting the roles of haptoglobin polymorphism, adipokines, resting heart rate, and walking speed.
Novel evidence on the diagnosis and treatment of patients with diabetes mellitus (DM) and metabolic syndrome is presented. Most patients with ischaemic heart disease present several comorbidities, including DM, which may interact with ischaemic injury and aggravate the prognosis.1 The complex pathophysiology and poor prognosis of ischaemic heart disease among people with DM involves the interaction of DM with ischaemia–reperfusion injury and cardioprotective mechanisms.2 Reducing the outcomes of ischaemia–reperfusion injury using targeted strategies would be particularly helpful in this population. In this issue, the protective interventional signalling pathways and mediators which are activated by ischaemic conditioning strategies in healthy and diabetic myocardium with ischaemia–reperfusion injury are reviewed.3 Cardiovascular disease (CVD) cannot be fully accounted for by traditional cardiovascular risk factors.4 Haptoglobin (Hp) polymorphism has been proposed as an independent predictor of CVD.5 There are two common alleles of the Hp gene: Hp1 and Hp2. A systematic review presented here shows that Hp2-1 individuals have a higher risk of hypertension and dyslipidaemia, while the Hp2-2 genotype has been associated with subclinical atherosclerosis, CVD and CVD mortality in type 2 DM.6 A potential benefit of vitamin E in the Hp2-2 genotype for cardiovascular complications in DM is proposed, but this warrants more consistent evidence. Adipose tissue acts as a dynamic endocrine organ producing adipokines, a family of peptides with heterogeneous metabolic activities. Here in a large cohort of 1215 individuals with clinically manifest CVD, adipokine profile was related to the metabolic syndrome: general and visceral adiposity, but not subcutaneous adiposity, was related to plasma concentrations of adipokines; adipose tissue (dys)function (as reflected by the adipokine profile) was more important than the quantity of adipose tissue in the relation with the metabolic syndrome. From the clinical perspective, adipokines could be proposed as biomarkers to estimate changes in adipose tissue volume and distribution, and to gain insight into residual cardiometabolic risk.7,8 CVD prevention guidelines recommend to deliver the most intensive preventive therapies to those at highest global cardiovascular risk, regardless of the relative weight of the single risk factors; 9 to increase adherence and reduce the gaps between indicated and used therapy, a polypill (containing aspirin, a statin and blood pressure lowering) has been indicated.10 The use of polypill components was assessed between 1996 and 2015 in patients with DM enrolled in the prospective SMART cohort, observing the frequent use of polypill components, often together with oral glucose-lowering agents, and this rate of use has increased steadily during the follow-up time. Lifestyle interventions play an important part in the treatment of DM and should not be neglected, which might be a risk when introducing a polypill.11 Few studies have compared population-level epidemiological surveillance indicators of the two diseases: based on population-based registries in northern France (Lille), it was found that the incident rates of acute coronary event and stroke were similar except under 60 years, where (35–59 years) the incident rate of acute coronary events was 1.6-fold higher than that of stroke. However, the mortality rate was 2.2-fold higher for acute coronary events than for stroke. The missed targets for secondary prevention in the majority of the patients after an acute coronary event have been advocated.12 A large-scale dataset of data in participants on average 58 years old, with no prior CVD, who underwent a heart rate (HR) measurement and were followed up for 3 years, showed that HR was on average higher in women (77.9 bpm) than in men (74.6 bpm). In both genders, a higher resting HR was a potent prognostic marker for cardiovascular events, with highly significant effects in fully adjusted models, mostly pronounced in heart failure and coronary death. Interestingly, disparities were found between women, in whom the threshold of 80 bpm was found for risk, and men, in whom the threshold was lower (70 bpm). Increased HR is associated with prothrombotic state,13 but the quality and temperature of air have important effects on cardiovascular function, including measures of HR.14 The walking speed maintained during a moderate 1-km walk was inversely related to all-cause hospitalisation in patients with arterial hypertension and CVD. The higher the baseline walking speed, the lower the relative risk of hospitalisation, and the shorter the length of hospital stay. These findings provide further support to the prognostic relevance of walking speed in outpatients with CVD.15 The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The author(s) received no financial support for the research, authorship, and/or publication of this article.
No takes yet. Share an insight, caveat, or question.
Massimo Piepoli (2018) conducted an editorial in Diabetes mellitus and cardiovascular disease. This editorial reviews novel evidence on cardiovascular risk factors, including haptoglobin polymorphism, adipokine profiles, polypill use, and resting heart rate in patients with diabetes and CVD.
Synapse has enriched 10 related papers. Consider them for comparative context: